Prime Highlights
- Vayalil said the group maintained uninterrupted care and delivered solid performance despite a challenging regional backdrop.
- Vayalil said the $500 million Sukuk attracted strong investor demand, boosting financial flexibility for future growth.
Key Facts
- Burjeel Holdings is a leading super-specialty healthcare services provider operating across the GCC region.
- The group’s multi-organ transplant programme has performed 86 transplants since inception.
Background
Burjeel Holdings, a leading super-specialty healthcare provider in the GCC, reported resilient financial performance for the first half of 2026, with total revenue rising 4.4% year-on-year to AED2,794 million (USD760.79 million), supported by patient visits exceeding 3.7 million, up 9.9%.
The company said growth was driven by expanding community access to specialised services, resilient operations and rising contributions from newly opened facilities. EBITDA excluding one-off items rose 24.6% to AED517 million, helped by the ramp-up of growth assets and continued cost optimisation. Performance strengthened through the second quarter, with revenue up 3.7% year-on-year and patient visits accelerating to 12.4% growth, led by stronger inpatient activity as inpatient revenue climbed 11.9% on higher surgical volumes and complex cases. Excluding the impact of the Unified Procurement Program introduced last August, normalised revenue rose 8.6% in the second quarter and 9.1% for the half-year.
The group advanced its clinical capabilities across oncology, transplantation and complex care, with its multi-organ transplant programme reaching 86 procedures since inception. It also became the first institution globally to administer camizestrant using ctDNA-guided treatment and launched a dedicated Sarcoma & Bone Center. The company expanded its network by opening a new medical centre in Dubai Silicon Oasis and a flagship aesthetics centre in Jumeirah, alongside new partnerships with Roswell Park Comprehensive Cancer Center and EDGE Group.
Chairman and CEO Dr Shamsheer Vayalil said the first half showed the resilience of Burjeel’s integrated healthcare platform despite a challenging regional backdrop, adding that the company’s inaugural $500 million Sukuk had attracted strong investor demand and would support its next phase of growth.
